Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients - PubMed (original) (raw)
. 2008 Jun 25;3(6):e2516.
doi: 10.1371/journal.pone.0002516.
Anupa Kamat, Kevin J Kunstman, Eun-Young Kim, Patrick Autissier, Alysse Wurcel, Tauheed Zaman, David Stone, Megan Mefford, Susan Morgello, Elyse J Singer, Steven M Wolinsky, Dana Gabuzda
Affiliations
- PMID: 18575590
- PMCID: PMC2424175
- DOI: 10.1371/journal.pone.0002516
Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients
Petronela Ancuta et al. PLoS One. 2008.
Abstract
Elevated plasma lipopolysaccharide (LPS), an indicator of microbial translocation from the gut, is a likely cause of systemic immune activation in chronic HIV infection. LPS induces monocyte activation and trafficking into brain, which are key mechanisms in the pathogenesis of HIV-associated dementia (HAD). To determine whether high LPS levels are associated with increased monocyte activation and HAD, we obtained peripheral blood samples from AIDS patients and examined plasma LPS by Limulus amebocyte lysate (LAL) assay, peripheral blood monocytes by FACS, and soluble markers of monocyte activation by ELISA. Purified monocytes were isolated by FACS sorting, and HIV DNA and RNA levels were quantified by real time PCR. Circulating monocytes expressed high levels of the activation markers CD69 and HLA-DR, and harbored low levels of HIV compared to CD4(+) T-cells. High plasma LPS levels were associated with increased plasma sCD14 and LPS-binding protein (LBP) levels, and low endotoxin core antibody levels. LPS levels were higher in HAD patients compared to control groups, and were associated with HAD independently of plasma viral load and CD4 counts. LPS levels were higher in AIDS patients using intravenous heroin and/or ethanol, or with Hepatitis C virus (HCV) co-infection, compared to control groups. These results suggest a role for elevated LPS levels in driving monocyte activation in AIDS, thereby contributing to the pathogenesis of HAD, and provide evidence that cofactors linked to substance abuse and HCV co-infection influence these processes.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
Figure 1. Increased plasma LPS, sCD14, and CCL2 are associated with HAD.
(A) Levels of LPS, sCD14, CCL2, and IL-6 were quantified in plasma of AIDS patients (n = 119) and uninfected controls (n = 25). (B) Spearman correlation (r and p-values) was calculated to determine the relationship between the LPS levels and sCD14, and between sCD14 and plasma CCL2 or IL-6. (C) Levels of plasma VL, CD4 counts, LPS, sCD14, CCL2, and IL-6 were compared in AIDS patients classified in 5 groups based on the degree of neurocognitive impairment (NCI) (None, No NCI; HAD, HIV-associated dementia; MCMD, minor cognitive and motor disorder; NPI-O, neuropsychiatric impairment due to conditions other than HIV; and ANI, asymptomatic NCI). Kruskal-Wallis test determined significant differences between the 5 groups in 1C. Median values in 1A and 1C are indicated as horizontal lines and significant differences between the 4 NCI groups versus the no NCI group (None) were determined using the Mann-Whitney test.
Figure 2. Substance abuse and HCV co-infection are associated with high plasma LPS levels.
(A) CD4 counts and plasma levels of VL, LPS, and sCD14 were compared in AIDS patients with or without substance abuse as indicated. (B) CD4 counts and plasma levels of VL, LPS, and sCD14 were compared in AIDS patients with IVDU heroin (H), cocaine (C), and H+C. (C) CD4 counts and plasma levels of VL, LPS, and sCD14 were compared in AIDS patients with and without HCV co-infection. Median values are indicated as horizontal lines and statistical significance between groups was calculated using the Mann-Whitney test; significant differences (p<0.05) are indicated.
Figure 3. Increased plasma lipopolysaccharide binding protein (LBP) levels in AIDS patients with HAD.
(A) LBP levels were quantified in plasma from AIDS patients (n = 119) and uninfected controls (n = 14) by ELISA. (B) Spearman correlation (r and p-values) was calculated to determine relationships between LBP levels and plasma LPS. (C) LBP levels were compared between AIDS patients classified into 5 groups based on the level of NCI as in Figure 1C or (D–E) classified into groups based on patterns of substance abuse as in Figure 2A–B. Median values are indicated as horizontal lines and statistical significance between groups was calculated using the Mann-Whitney test; significant differences (p<0.05) are indicated.
Figure 4. Decreased plasma IgM endotoxin core antibody (EndoCAb) levels in AIDS patients with HAD.
(A) Levels of IgM EndoCAb were quantified in plasma from AIDS patients (n = 119) and uninfected controls (n = 14) by ELISA. (B) Spearman correlation (r and p-values) was calculated to determine relationships between IgM EndoCAb levels and plasma LPS. (C) IgM EndoCAb levels were compared between AIDS patients classified into 5 groups based on the level of NCI as in Figure 1C or (D–E) classified into groups based on patterns of substance abuse as in Figure 2A–B. Median values are indicated as horizontal lines and statistical significance between groups was calculated using the Mann-Whitney test; significant differences (p<0.05) are indicated.
Figure 5. Increased CD16+ monocyte frequency in AIDS patients with and without HAD.
(A) The frequency of CD16+ Mo within the total Mo population was analyzed in AIDS (n = 38) and uninfected subjects (n = 25). Total and CD16+ Mo were distinguished from granulocytes by HLA-DR and lack of CD16b/CD66b expression, and from NK cells by higher forward and side scatter characteristics (FSC and SSC), CD14, CD4, and CD33, and lack of CD56 expression . (B) The frequency of CD16+ Mo was compared in AIDS patients with HAD (n = 29) and no NCI (n = 9). (C) The frequency of CD16+ Mo, plasma VL, and plasma levels of LPS and sCD14 were compared in patients receiving HAART ≥8 weeks (wks) and untreated or on HAART <8 wks. Median values are indicated as horizontal lines and statistical significance between groups was calculated using the Mann-Whitney test; significant differences (p<0.05) are indicated.
Figure 6. Upregulation of CD69 and CCR5 expression on CD16+ and CD16− monocyte subsets.
(A) PBMC from AIDS subjects were stained with fluorochrome-conjugated Abs. CD14 and CD16 expression identified three Mo subsets: CD14highCD16− (gate R2), CD14highCD16+ (gate R3), and CD14lowCD16+ (gate R4). (B) The frequency of each Mo subset was compared in AIDS (n = 11) and uninfected subjects (n = 8). The expression of CD69 (C) and CCR5 (D) was analyzed for each Mo subset from AIDS (n = 9–11) and uninfected subjects (n = 5–9). Median values are indicated as horizontal lines, and statistical significance in 6B–D was calculated using the Mann-Whitney test.
Figure 7. Monocytes are a minor reservoir for HIV replication compared to CD4+ T-cells in vivo.
Highly pure CD4+ T-cells and total or CD16+ and CD16− Mo subsets were sorted from the same donor peripheral blood sample by FACS from HIV-infected patients with (n = 12) or without (n = 1) AIDS. 8 of the 12 AIDS subjects had HAD. Levels of cell-associated (A) HIV DNA and (B) RNA were quantified by real time PCR and RT-PCR, respectively. (C) CD4+ T-cells and CD16+ or CD16− Mo (105 cells/well) from patients with high plasma VL were co-cultured with PHA/IL-2 activated Mo∶CD4+ T-cell co-cultures from HIV-uninfected subjects (Mo∶T-cell ratio of 1∶2; 0.5×106 cells/well). Co-cultures were maintained up to 32 days and supernatants were recovered every 4 days. Shown are levels of HIV-p24 in supernatants quantified by ELISA at days 24, 28, and 32.
Similar articles
- Myeloid and lymphoid activation markers in AIDS and non-AIDS presenters.
Iannetta M, Savinelli S, Rossi R, Mascia C, Marocco R, Vita S, Zuccalà P, Zingaropoli MA, Mengoni F, Massetti AP, Falciano M, d'Ettorre G, Ciardi MR, Mastroianni CM, Vullo V, Lichtner M. Iannetta M, et al. Immunobiology. 2019 Mar;224(2):231-241. doi: 10.1016/j.imbio.2018.11.011. Epub 2018 Nov 28. Immunobiology. 2019. PMID: 30522891 - Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.
Sánchez-Ramón S, Bellón JM, Resino S, Cantó-Nogués C, Gurbindo D, Ramos JT, Muñoz-Fernández MA. Sánchez-Ramón S, et al. Pediatrics. 2003 Feb;111(2):E168-75. doi: 10.1542/peds.111.2.e168. Pediatrics. 2003. PMID: 12563091 - Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients.
Papasavvas E, Pistilli M, Reynolds G, Bucki R, Azzoni L, Chehimi J, Janmey PA, DiNubile MJ, Ondercin J, Kostman JR, Mounzer KC, Montaner LJ. Papasavvas E, et al. AIDS. 2009 Jan 28;23(3):369-75. doi: 10.1097/QAD.0b013e32831e9c76. AIDS. 2009. PMID: 19114856 Free PMC article. - HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications.
Valcour VG, Shiramizu BT, Shikuma CM. Valcour VG, et al. J Leukoc Biol. 2010 Apr;87(4):621-6. doi: 10.1189/jlb.0809571. Epub 2010 Feb 3. J Leukoc Biol. 2010. PMID: 20130221 Free PMC article. Review. - Circulating LPS and (1→3)-β-D-Glucan: A Folie à Deux Contributing to HIV-Associated Immune Activation.
Ramendra R, Isnard S, Mehraj V, Chen J, Zhang Y, Finkelman M, Routy JP. Ramendra R, et al. Front Immunol. 2019 Mar 18;10:465. doi: 10.3389/fimmu.2019.00465. eCollection 2019. Front Immunol. 2019. PMID: 30967860 Free PMC article. Review.
Cited by
- Medial prefrontal cortex connectivity with the nucleus accumbens is related to HIV serostatus, perceptions of psychological stress, and monocyte expression of TNF-a.
McIntosh R, Lobo J, Szeto A, Hidalgo M, Kolber M. McIntosh R, et al. Brain Behav Immun Health. 2024 Aug 22;41:100844. doi: 10.1016/j.bbih.2024.100844. eCollection 2024 Nov. Brain Behav Immun Health. 2024. PMID: 39328275 Free PMC article. - Changes in monocyte subsets in volunteers who received an oral wild-type Salmonella Typhi challenge and reached typhoid diagnosis criteria.
Toapanta FR, Hu J, Shirey KA, Bernal PJ, Levine MM, Darton TC, Waddington CS, Pollard AJ, Sztein MB. Toapanta FR, et al. Front Immunol. 2024 Aug 27;15:1454857. doi: 10.3389/fimmu.2024.1454857. eCollection 2024. Front Immunol. 2024. PMID: 39263222 Free PMC article. - HIV-associated neurocognitive disorder: key implications of the microbiota-gut-brain axis.
Hu A, Zaongo SD, Harypursat V, Wang X, Ouyang J, Chen Y. Hu A, et al. Front Microbiol. 2024 Aug 2;15:1428239. doi: 10.3389/fmicb.2024.1428239. eCollection 2024. Front Microbiol. 2024. PMID: 39155987 Free PMC article. Review. - Tryptophan-Kynurenine Pathway Activation and Cognition in Virally Suppressed Women With HIV.
Shorer EF, Dastgheyb RM, French AL, Daubert E, Morack R, Yohannes T, Clish C, Gustafson D, Sharma A, Rogando A, Qi Q, Burgess H, Rubin LH, Weber KM. Shorer EF, et al. J Acquir Immune Defic Syndr. 2024 Aug 15;96(5):494-500. doi: 10.1097/QAI.0000000000003454. Epub 2024 Jul 9. J Acquir Immune Defic Syndr. 2024. PMID: 38985447 Free PMC article. - A Perfect Storm: The Convergence of Aging, Human Immunodeficiency Virus Infection, and Inflammasome Dysregulation.
Thirugnanam S, Rout N. Thirugnanam S, et al. Curr Issues Mol Biol. 2024 May 15;46(5):4768-4786. doi: 10.3390/cimb46050287. Curr Issues Mol Biol. 2024. PMID: 38785555 Free PMC article. Review.
References
- Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol. 2006;7:235–239. - PubMed
- Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med. 2006;12:289–295. - PubMed
- Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–1371. - PubMed
- Cavaillon JM, Adrie C, Fitting C, Adib-Conquy M. Endotoxin tolerance: is there a clinical relevance? J Endotoxin Res. 2003;9:101–107. - PubMed
- Thieblemont N, Weiss L, Sadeghi HM, Estcourt C, Haeffner-Cavaillon N. CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection. Eur J Immunol. 1995;25:3418–3424. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R24 MH059724/MH/NIMH NIH HHS/United States
- R01 MH083588/MH/NIMH NIH HHS/United States
- R01 DA016549-02/DA/NIDA NIH HHS/United States
- DA016549/DA/NIDA NIH HHS/United States
- R24 MH059745/MH/NIMH NIH HHS/United States
- MH083588/MH/NIMH NIH HHS/United States
- MH59656/MH/NIMH NIH HHS/United States
- R01 DA016549-05/DA/NIDA NIH HHS/United States
- U01 MH083545/MH/NIMH NIH HHS/United States
- NS54591/NS/NINDS NIH HHS/United States
- MH 59745/MH/NIMH NIH HHS/United States
- R01 DA016549-03/DA/NIDA NIH HHS/United States
- R21 DA026322/DA/NIDA NIH HHS/United States
- MH59724/MH/NIMH NIH HHS/United States
- R01 DA016549-01/DA/NIDA NIH HHS/United States
- R24 NS038841/NS/NINDS NIH HHS/United States
- R21 DA026322-01/DA/NIDA NIH HHS/United States
- R01 DA016549-04/DA/NIDA NIH HHS/United States
- R21 DA026322-02/DA/NIDA NIH HHS/United States
- NS060611/NS/NINDS NIH HHS/United States
- NS38841/NS/NINDS NIH HHS/United States
- R01 DA016549/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous